Tipharco Pharmaceutical Joint Stock Company (DTG) hereby provides an explanation to the State Securities Commission, the Hanoi Stock Exchange, and esteemed shareholders regarding the fluctuations in revenue and profit after tax in the Q1 2025 financial statements compared to the same period in 2024 as follows:

In the first quarter of 2025, net revenue reached VND 58.3 billion, equivalent to only 87.34% of Q1 2024, reflecting the challenging business environment during the first three months of the year. Slower consumption in traditional markets and heightened industry competition leading to a shift in revenue structure were the main reasons behind the decline in both revenue and profit during the reporting period.

Moving forward, the Company will continue to review the performance of each business channel, tighten cost control, and focus on promoting high-margin product groups to help re-store business results in the upcoming quarters.

Thank you very much./.

Financial Statements for the First Quarter of 2025